Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands

Based on the current Hungarian Summary of Product Characteristics for Zemplar (paricalcitol injection), the patient is entitled to treatment with paricalcitol injection and: 1. ≥ 18 years of age, 2. Willing to sign the patient information and informed consent form, 3. Chronic kidney disease (CKD) stage 5 patient receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT), whose intact parathyroid hormone (iPTH) level is: * between 500-800 pg/mL with at least two abruption of conventional vitamin D therapy due to elevated serum calcium level (i.e. \> 2.4 mmol/L) in the medical history, or * higher than 800 pg/mL and parathyroidectomy is contraindicated. 4. The patient is planned to receive paricalcitol treatment independently from his/her participation in this study.

Patients cannot be enrolled in the study if any of the following exclusion criteria apply: 1. The patient is already treated with Zemplar (paricalcitol injection), 2. Any contraindication exists as stated in the current Hungarian Summary of Product Characteristics for Zemplar (paricalcitol injection), 3. Patients who decline to participate in the study or decline to sign the patient information/informed consent form.